Genocea Biosciences (NASDAQ:GNCA) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Genocea Biosciences Stock Performance

The company has a market cap of $6,000.00, a P/E ratio of 0.00 and a beta of 1.61. Genocea Biosciences has a 52-week low of $0.00 and a 52-week high of $0.00. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.35 and a current ratio of 1.35.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.